Wall Street brokerages predict that VBI Vaccines Inc (NASDAQ:VBIV) will post earnings of ($0.05) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.05) to ($0.04). VBI Vaccines reported earnings of ($0.13) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 61.5%. The firm is expected to issue its next earnings results on Friday, August 14th.
According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.19) per share for the current fiscal year, with EPS estimates ranging from ($0.22) to ($0.16). For the next fiscal year, analysts expect that the firm will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.22) to ($0.15). Zacks’ EPS averages are a mean average based on a survey of research firms that cover VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.83 million. VBI Vaccines had a negative return on equity of 57.79% and a negative net margin of 2,133.79%.
Shares of VBIV traded up $0.23 during trading on Friday, reaching $2.99. The company’s stock had a trading volume of 37,257,365 shares, compared to its average volume of 9,694,090. The company has a market cap of $636.59 million, a price-to-earnings ratio of -8.54 and a beta of 1.70. The company has a quick ratio of 1.28, a current ratio of 1.30 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $2.20 and a two-hundred day moving average of $1.47. VBI Vaccines has a twelve month low of $0.47 and a twelve month high of $3.50.
In other VBI Vaccines news, major shareholder Life Sciences Maste Perceptive acquired 9,090,909 shares of the stock in a transaction that occurred on Friday, April 24th. The stock was acquired at an average price of $1.21 per share, with a total value of $10,999,999.89. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in VBIV. Rhumbline Advisers increased its position in VBI Vaccines by 11.5% in the fourth quarter. Rhumbline Advisers now owns 70,975 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 7,328 shares during the period. Oppenheimer & Co. Inc. lifted its position in VBI Vaccines by 64.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 10,300 shares during the last quarter. Citigroup Inc. grew its position in VBI Vaccines by 35.7% in the 1st quarter. Citigroup Inc. now owns 52,170 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 13,716 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of VBI Vaccines by 61.3% during the first quarter. BNP Paribas Arbitrage SA now owns 47,345 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 17,995 shares during the period. Finally, Cetera Advisor Networks LLC increased its position in VBI Vaccines by 95.1% in the 4th quarter. Cetera Advisor Networks LLC now owns 38,602 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 18,815 shares during the period. Institutional investors and hedge funds own 33.88% of the company’s stock.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Story: What is quantitative easing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.